NYSE · DGX

Quest Diagnostics Inc.

$227.86 -$0.04 (-0.02%) 1D After hours
Session Pulse Overnight session 1 mentions on Wed · 1 bullish / 0 bearish tags No new SEC filings since Mon close its sector ranked 6/11 this week Full pulse →
Charting by TradingView

Key Metrics

$25.07B
Market cap
24.48×
P/E · TTM
$11.28B
Revenue · TTM
$1.02B
Net income
EPS · TTM $9.06
Dividend yield 1.4%
Free cash flow $1.33B
Beta · 1Y -0.21
EBITDA · TTM $2.19B
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 23
    The stock moved +8.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 23
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$25.07B
Enterprise value$30.33B
Shares outstanding110.0M
52-wk range$165.78 – $237.78
Avg volume · 20D1.0M
Net cash −$5.27B
Book value / share$65.19
IndustryServices-Medical Laboratories
ExchangeNYSE
About Quest Diagnostics Inc.
IPO dateDec 17, 1996
Employees57000

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E24.48
P/S2.22
P/FCF18.91
EV/EBITDA13.88
EV/Sales2.69
Graham №$115.29

Profitability

Gross —
Operating 14.3%
Net 9.1%
FCF 11.8%
ROE / ROIC 14.5% · 9.7%

Financial Health

Current ratio1.18
Quick ratio1.08
Debt / equity0.77
Debt / EBITDA 2.59
Net cash −$5.27B
Working capital$389.00M

Cash Flow · TTM

Operating CF $1.85B
Capex −$524.00M
Free cash flow $1.33B
Buybacks —
Dividends paid $357.00M
Shareholder yield 1.4%

Piotroski F-Score

6 / 9
Middling fundamentals · 6 of 9 signals passing

Altman Z-Score

—
Insufficient balance-sheet inputs

Graham Number vs Price

$115.29 vs $227.86
Trades 2.0× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings